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Abstract
Background: Major histocompatibility complex proteins are believed to undergo significant conformational changes
concomitant with peptide binding, but structural characterization of these changes has remained elusive.
Methodology/Principal Findings: Here we use molecular dynamics simulations and experimental probes of protein
conformation to investigate the peptide-free state of class II MHC proteins. Upon computational removal of the bound
peptide from HLA-DR1-peptide complex, the a50-59 region folded into the P1-P4 region of the peptide binding site,
adopting the same conformation as a bound peptide. Strikingly, the structure of the hydrophobic P1 pocket is maintained
by engagement of the side chain of Phe a54. In addition, conserved hydrogen bonds observed in crystal structures between
the peptide backbone and numerous MHC side chains are maintained between the a51-55 region and the rest of the
molecule. The model for the peptide-free conformation was evaluated using conformationally-sensitive antibody and
superantigen probes predicted to show no change, moderate change, or dramatic changes in their interaction with
peptide-free DR1 and peptide-loaded DR1. The binding observed for these probes is in agreement with the movements
predicted by the model.
Conclusion/Significance: This work presents a molecular model for peptide-free class II MHC proteins that can help to
interpret the conformational changes known to occur within the protein during peptide binding and release, and can
provide insight into possible mechanisms for DM action.
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Introduction
Class II major histocompatibility complex (MHC) are hetero-
dimeric proteins which bind antigenic peptides as part of the
adaptive immune response to foreign pathogens. Upon binding
peptides derived from endosomes or the extracellular milieu, the
intact MHC II-peptide complex is displayed at the cell surface of
antigen presenting cells (APC) for surveillance by CD4+ T-cells
[1]. Interaction between the APC and its cognate CD4+ T-cell
leads to an effector response which then clears the body of the
invading pathogen.
Peptides bind to the MHC II in an extended polyproline type II
helix along a binding groove contributed to by both the alpha and
beta subunits. Crystal studies of allelic variants bound to a variety of
peptides has revealed a conserved hydrogen bonding network which
exists between the peptide backbone and main chain residues along
the helices of the alpha and beta binding domain [2]. Additionally,
binding energy is created by the interaction of peptide side chains
and pockets within the binding groove of the MHC II binding
domain. Residues lining these pockets vary between alleles which
thus lead to tremendous diversity within the peptide repertoire.
Generally, these pockets accommodate residue side chains from the
peptide at the P1, P4, P6 and P9 positions with smaller pockets or
shelves in the binding site accommodating the P3 and P7 residues;
these pockets are numbered along the peptide relative to a large
usually hydrophobic pocket near the peptide binding site. For DR1
(DRB1*0101), a common human class II MHC protein and the
subject of this study, the P1 pocket shows a strong preference for
large hydrophobic side chains (Trp, Tyr, Phe, Leu and Ile), the P6
pocket has a strong preference for smaller residues (Gly, Ala, Ser
and Pro) and the P4 and P9 pockets have weaker preference for
residues with some aliphatic character [3].
Although there is little structural variation observed among
crystal structures determined for MHC II-peptide complexes,
numerous studies have reported alternate conformations for
particular MHC II-peptide complexes [4,5,6,7] and for peptide-
free MHC II molecules [8,9]. Peptide-free DR1 has been shown to
have a larger hydrodynamic radius than the peptide loaded form
(29 vs 35 A˚), as well as a decrease in helicity as measured by
circular dichroism [9,10]. These differences are reversed upon
binding peptide. Peptide binding and dissociation experiments
have shown that peptide-free MHC II can adopt two intercon-
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verting forms, one receptive to and one averse to peptide loading
[11,12,13]. The receptive state is able to bind peptide rapidly, but
will convert to the peptide averse form within minutes if not
stabilized by peptide or by association with the chaperone HLA-
DM. It has been proposed that HLA-DM mediates its function by
shifting the equilibrium of peptide averse to a peptide receptive
state; however, the peptide loading process is still relatively
undefined [14,15]. In order to gain a better understanding of this
process, it is necessary to develop a more detailed understanding
into the structural changes that exist based on peptide occupancy.
Previous work using conformationally sensitive monoclonal
antibodies raised against the b chain of DR1 has revealed that a
noncontiguous epitope in the peptide binding region (residues
b53–67) and another in the lower Ig-like domain (residues b186–
189) are accessible only in the peptide-free conformation [16].
Another study which used differential chemical modification found
residues a50,67, b98,189 selectively modified in peptide-free but
not peptide-loaded DR1 [17]. Although these studies helped to
define regions within the structure that change upon the peptide
occupancy state, there is not enough information to generate a
working model of the peptide-free DR1. Molecular dynamics
simulations have been used to gain insight into conformational
changes relative to an experimentally defined structure [18,19].
Combined with experimental support, models developed from this
method can be substantiated. In this study, we performed
molecular dynamics simulation of DR1 in both the peptide-free
and peptide-loaded states. Several regions of DR1 were predicted
by this analysis to change conformation substantially upon loss of
bound peptide. Differential binding of conformationally-specific
antibody and superantigen probes to the peptide-free and peptide-




DR1 was expressed, purified and folded as previously described
[20]. Briefly, the extracellular domains of DR1 subunits were
expressed individually as inclusion bodies in Escherichia coli.
Subunits were purified by anion exchange chromatography and
then diluted into folding buffer in the presence or absence of a 5
fold molar excess of the HA peptide (PKYVKQNTLKLAT).
Folded peptide-free or peptide-loaded DR1, was purified by
affinity chromatography on an LB3.1-protein column and by gel-
filtration chromatography to remove any aggregated protein.
Pooled fractions were concentrated to 1 mg/ml and stored at 4uC.
For some SPR studies, DR1 with a cysteine modification at the C-
terminus of the alpha subunit was prepared by expression in insect
cells as previously described [21] Briefly, DR1-acys was expressed
in S2 insect cells in serum free medium and purified from culture
supernatant by LB3.1 affinity and gel filtration chromatography.
This material is substantially free of peptide [22]. To generate
loaded complex, purified DR1acys was incubated with excess
peptide in binding buffer (100 mM phosphate pH 5.0, 0.02%
NaN3, 1 mM EDTA, 50 mMNaCl, 0.05% octyl glucoside, 2 mM
dithriothreitol (DTT), 0.01 mg/ml PMSF) for 3 days at 37uC.
Peptide-free and peptide-loaded DR1acys were purified as
described above for E. coli derived protein.
ELISA
A sandwich ELISA was used to measure binding of peptide-free
or peptide-loaded DR1 to LB3.1 and MEM264 as previously
described [22]. Plates were developed with ABTS and read on a
Polarstar plate reader (BMG Labtech) at 405 nm absorbance.
Half-maximal binding concentrations were obtained from a 4-
parameter binding equation fit to the data.
Biacore
We used a BIAcore 2000 surface plasmon resonance biosensor
for the SEC3 experiments and a Biacore 3000 for all other SPR
experiments (Biacore AB, Uppsala, Sweden). Biotinylated DR1
was immobilized using Sensor Chip SA. All other experiments
used standard carbodiimide-mediated amine coupling to Sensor
Chip CM-5. Data were background-subtracted using an unmod-
ified reference surface. The data were fit to the 1:1 binding with
baseline drift model provided by BiaEval software. Fit residuals are
shown in the figure and generally represent ,10% of the overall
signal. The LB3.1 and MEM264 were regenerated with 20 mM
NaOH for 1.5 or 1 minutes respectively, followed by a 2 minute
stabilization in running buffer. For the other SEC3 and DR1
surfaces, bound protein eluted rapidly and a separate regeneration
protocol was not needed.
Molecular Dynamic Simulation
Each simulated system consisted of one protein molecule in a
cubic box with a distance of 3.0 nm from its periodic image, with
approximately 30,200 molecules of water. Coordinates for the
peptide-bound form of DR1 were downloaded from the Protein
Data Bank (PDB code: 1SJE) [23]. The peptide-free form of the
DR1 was prepared by removing the sixteen residue peptide from
the peptide-binding grove. SEC3 was removed from both
structures.
The energy of the system was minimized with the steepest
descent algorithm, followed by a 600 ps of positional restraint
dynamics to generate the starting point for molecular dynamics.
The GROMOS9643a1 force field [24] was used, and all
simulations were carried out at constant temperature (298 K),
pressure (1 atm), and number of molecules using a Berendsen weak
coupling bath with a coupling constant of 0.1 ps for temperature
and 0.5 ps for the pressure [25]. A twin range cut-off of 0.9/
1.4 nm for van der Waals interactions was applied, and the
particle mesh Ewald algorithm was used for long range
electrostatic interactions [26]. Neighbor lists were utilized and
updated every five steps, and all protein and water bond lengths
were constrained using the LINCS and SETTLE algorithm,
respectively [27].
The length of the simulation was determined by monitoring the
convergence of various mechanical properties of the system. The
simulation was stopped when the value for the root mean square
deviation (RMSD) did not fluctuate more than 3.0 A´˚ from its
average value during 2 ns. As described [28], if the simulation
reached an RMSD that oscillates around a constant value, it can
be assumed the system has converged to a stable or a metastable
structure. For both systems, the simulations were terminated after
60 ns with a time step of 2 fs. The coordinates were saved every
five picoseconds and the analysis was performed using GRO-
MACS v.3.2.1 simulation package [29]. All molecular graphics
images were generated using the Visual Molecular Dynamics
(VMD) software [30].
Results
Modeling the structure of the peptide-free form of HLA-
DR1 by molecular dynamics
A model for the peptide-free structure of DR1 was obtained by
molecular dynamics simulation starting from the X-ray coordi-
nates of a DR1-peptide complex (PDB Code: 1SJE, [31]) from
which peptide was removed before the start of the simulation. A
Model for Empty MHC II
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parallel simulation was started from the same coordinates but
without the removal of peptide. Simulations were carried out in a
water-filled box at constant temperature and pressure using the
GROMOS force field [29] and 2 fs time steps. During the
simulation, the total root mean square deviation, RMSD, from the
starting coordinates was followed in various regions of the protein,
Fig. 1A–1C. Large changes in RMSD were observed over the first
5–10 ns, particularly in the a1b1 peptide binding domain and the
lower b2 immunoglobulin-like domain, with much smaller
fluctuations occurring thereafter. The models were investigated
in detail at the 10 ns time point, as described below.
RMS fluctuations during the first 10ns of the peptide-loaded
and peptide-free simulations are shown in Fig. 1D and E as a
function of residue number. A trajectory of the simulation is
depicted in Fig. 1F for the peptide-free and in Fig. 1G for the
peptide-loaded dynamics runs. Panels H and I show a different
view highlighting the peptide binding region. In the peptide-
binding site, significant movements can be seen in the a-helices of
the peptide-free form, as compared to those of the peptide-loaded
form, which do not fluctuate or move as much. In the a subunit,
the principle differences between the peptide-loaded and peptide-
free simulations were in the region a34-60 (light arrows). This
region, part of the peptide binding domain, corresponds to the last
two strands of the beta sheet ‘‘floor’’ and the first half of the a
helical region forming one side of the peptide binding site. In the b
subunit the largest RMS fluctuations were in the lower b2
immuoglobulin domain, residues b90–110, and were observed in
both peptide-loaded and peptide-free simulations (Fig. 1C and E,
asterisk). Different orientations of the b2 domain relative to the
peptide binding domain already have been observed in different
HLA-DR1 crystal structures, reflecting orientational flexibility in
this domain (Fig. S1). Elsewhere in the b-subunit, large RMS
Figure 1. Molecular dynamics simulation of peptide-bound and peptide-free DR1. A, (A–C) RMS deviation over time for the peptide-
loaded (red) and peptide-free (black) simulations, for the a1b1 peptide-binding domain (A), the Ig-like a2 domain (B), and the Ig-like b2 domain (C).
D–E, Root mean square (RMS) fluctuation during the simulation for each residue (all atoms included) for the a (D) and b (E) subunits. (F–I) Molecular
dynamic trajectories for the peptide-loaded (F,H) and peptide-free (G,I) form of DR1. Initial states shown in blue, final states shown in red, with a linear
interpolation of conformations between the initial and final structures shown in other colors. (F,G), Side view of entire protein, (H,I) Top view of
peptide binding site only.
doi:10.1371/journal.pone.0002403.g001
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fluctuations were observed for the region b50-70 in the peptide
binding site. In this region larger deviations were observed in the
peptide-free as compared to the peptide-loaded simulation
(Fig. 1F–I). A difference distance matrix plot [32] calculated at
10ns highlights the regions that are different in this simulated
peptide-loaded and peptide-free forms (Fig. S2).
Motion of the a50-59 region into the amino-terminal end
of the peptide binding site
The major conformational alteration observed during the
simulations is a narrowing of the N-terminal region of the
peptide-binding site (Fig. 2A). This narrowing of the site occurred
early during the dynamics simulations run in the absence of
peptide, and persisted throughout the entire 60ns time course.
Such narrowing was not observed during dynamics simulations of
the peptide-loaded form (Fig. 2B), although at late time points
(.15 ns) the peptide-loaded simulation occasionally sampled
conformations having some characteristics of the peptide-free
form (not shown). In the model of the peptide-free form of DR1
derived by molecular dynamics simulation, the peptide binding
site is dramatically altered as compared to the highly stereotyped
conformation observed in crystal structures of the peptide-bound
form. During the simulation, the a50-59 region of DR1 moves to
fill the amino-terminal end of the peptide-binding site occupying,
in part, the area where the antigenic peptide is usually found
(Fig. 3). The amino-terminal region of the peptide-binding site of
HLA-DR1 was previously suggested to be more flexible upon
peptide-removal in a normal mode analysis [33] as well as in
another molecular dynamics calculation [34]. In our model, a
sharp kink forms at Gly a58, allowing the region a50-59 to fold
into the binding site, taking the place of the bound peptide in the
P1 to P4 region. Smaller changes but still significant changes are
Figure 2. Motion of a50-59 into the peptide binding site during molecular dynamics in the absence of peptide. (A), Ribbon diagram of
peptide-free DR1 before and after molecular dynamics simulations, showing residues at N-terminal end (magenta, a52-57 and b79-83), central region
(green, a62-66 and b65-69), or C-terminal end (blue, a71-75 and b58-62) of peptide binding site, used to calculate distances across the binding site
(indicated by arrows). (B), Changes during molecular dynamics simulation of distances across the peptide binding site at three different locations,
colored as indicated in panel A.
doi:10.1371/journal.pone.0002403.g002
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Figure 3. Comparison of models for peptide-loaded and peptide-free DR1. A, Ribbon diagram of DR1 (blue) bound to the HA-peptide. The
peptide is shown as stick with carbon atoms in white; and nitrogen and oxygen atoms in blue and red, respectively. Pocket locations within the
peptide-binding site are labeled. B, Ribbon diagram of the peptide-free HLA-DR1 (red). C,D, hydrogen-bonding interactions for the peptide-loaded (C)
and peptide-free (D) proteins. E,F Surface side-view of the N-terminal region of the peptide-binding site for the peptide-loaded (E) and peptide-free
(F) proteins. In (D and F), a50-59 of the peptide-free form is shown in stick representation as for the HA peptide. Figures were generated using PyMol
[58]
doi:10.1371/journal.pone.0002403.g003
Model for Empty MHC II
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observed in the helical regions that flank a50-59, in the adjacent
a46-49 loop, and in beta subunit helical regions (compare Fig. 3A
and B).
After moving into the peptide-binding site, the main chain of
the a50-59 region is able to satisfy essentially all of the hydrogen
bonds in this region lost upon removal of the peptide. In the
conserved arrangement observed in class II MHC-peptide crystal
structures, the backbone of a bound antigenic peptide forms six
hydrogen bonds with the side chains of non-polymorphic DR1
residues Gln a9, Arg b71, His b81 and Asn b82 (Fig. 3C). In the
molecular dynamics model of the peptide-free form of DR1, each
of these hydrogen-bonding interactions is observed, by direct
hydrogen bonding between the main chain atoms of DR1 a53-57
and side chains of Gln a9, Arg b71, His b81 and Asn b82 (Fig. 3D).
Movement of the a50-59 region into the peptide binding site
also results in occupancy of the P1-P4 side-chain binding pockets.
These pockets line the peptide binding site, and accommodate side
chains of the bound peptide. The P1 pocket of DR1 is the major
determinant of peptide binding, and usually accommodates a large
hydrophobic side chain [10]. In the molecular dynamics model of
the peptide-free form of DR1, the side chain of Phe a54 binds into
the P1 pocket, in the same orientation as observed for an aromatic
P1 residue from a crystal structure of peptide-loaded DR1
complexes (Fig. 3E and F). The P4 pocket is shallower than the
P1 pocket and open at the end, and in DR1 exhibits a weaker
preference for residues with some aliphatic character. In the
molecular dynamics model of the peptide-free form of DR1, the
side chain of Gln a57 binds into the P4 pocket, essentially identical
to Gln at the corresponding position in a bound peptide.
Experimental probes of conformational differences
between peptide-free and peptide-loaded HLA-DR1
We attempted to evaluate whether or not the striking alterations
predicted by the molecular dynamics simulations corresponded to
actual conformational differences between peptide-free and
peptide loaded proteins, using conformation-specfic superantigen
and antibody probes of DR1 structure. Superantigens are soluble
bacterial toxins that bind to class II MHC proteins and T cell
receptors, causing polyclonal T cell activation independent of
peptide antigen [35]. Superantigen binding sites on the DR alpha
subunit have been determined by X-ray crystallography of
superantigen-MHC-peptide complexes [36], but superantigen
binding to peptide-free DR1 has not been described. Conforma-
tion-specific antibody probe of DR1 structure also are available,
although the binding sites have been characterized only by
domain-swap or mutagenesis experiments. In general, most of
these antibodies bind to both peptide-free and peptide-loaded
DR1 [22]. MEM-264 and the related MEM-265, MEM-266, and
MEM-267 antibodies [16] are exceptions to this pattern, in they
preferentially bind to peptide-free DR1 Although differential
binding to peptide-free and peptide-loaded DR1 has been
described for these antibodies, there has not been a quantitative
comparison. Finally, LB3.1, a commonly used anti-DR antibody,
also has been reported to exhibit differences in reactivity with
peptide-free and peptide-loaded DR1 [16], although again a
quantitative analysis has not been reported. To evaluate in a
quantitivate manner the differential binding of these conforma-
tionally-specific superantigen and antibody probes, we used
surface plasmon resonance (SPR) to characterize their binding to
to peptide-free and peptide-loaded DR1 prepared by refolding
purified DR1 alpha and beta subunits in the absence or presence
of peptide (see Methods). As previously observed [9], the peptide-
free and peptide-loaded preparations exhibited characteristic
differences in hydrodynamic radius and stability to SDS-induced
subunit dissociation [20] (Fig. S3).
Staphylococcal Enterotoxin C3 (SEC3). The interaction of
the bacterial superantigen SEC3, a tight-binding derivative of
staphylococcal enterotoxin C3 (SEC3), with peptide loaded DR1
has been characterized previously by X-ray crystallography and
SPR experiments [37]. Contact residues between SEC3 and
peptide-loaded DR1 have been mapped by crystallography and by
mutagenesis, and include Tyr13, Asp17, Gln18, Met36, Ala37,
Leu60, Ile63, Ala64, and Lys67 on the a chain [36]. None of these
residues move appreciably during molecular dynamics simulation
of the empty protein. To evaluate this experimentally, peptide-free
and peptide-loaded DR1 were immobilized to a streptavidin-
dextran surface using a C-terminal biotin [21], and binding to
varying concentrations of soluble SEC3 was followed by SPR.
Essentially identical SEC3 binding behavior was observed for
peptide-free and peptide-loaded DR1 (Figure 4A–C). SPR data
were fit to a kinetic model, yielding apparent KD values for
peptide-free and peptide-loaded DR1 of 14 mM and 11 mM,
respectively. Equilibrium analysis of these same data yielded
apparent KD values of 6.1 and 8 mM. These values are similar to a
previously reported KD value for peptide-loaded DR1 binding to
SEC3, 4.6 mM [37]. To confirm these results, we performed this
experiment in the opposite orientation, with SEC3 immobilized
via standard amine coupling and with peptide-free or peptide-
loaded DR1 in the mobile phase. Again, we obtained similar KD
values for peptide loaded and peptide-free DR1 6.0 and 6.1 mM,
respectively (Table 1). Overall these data demonstrate that SEC3
binding does not distinguish between peptide-loaded and peptide-
free DR1. Because this epitope is not predicted to move upon
release of peptide, these observations are consistent with the
model.
Monoclonal antibody MEM-264. MEM-264 is a
monoclonal antibody that previously has been shown to bind
specifically to the peptide-free conformation of DR1 [16]. The
MEM-264 epitope has been mapped by overlapping peptides and
alanine scanning mutagenesis, and corresponds to a discontinuous
region on the b subunit helical region including residues 53–67
[16]. In the molecular dynamics model for peptide-free DR1, this
entire region is predicted to move significantly relative to the rest
of the b subunit. We performed a SPR binding analysis with
immobilized MEM-264 and either peptide-free or loaded DR1 in
the mobile phase (Fig. 4D and E). We found robust binding to
immobilized MEM-264 for peptide-free DR1, with an apparent
KD of approximately 24 nM. Peptide-loaded DR1 did not bind to
MEM-264 at concentrations up to 2 mM. In addition, we
compared binding of peptide-free and peptide-loaded DR1 using
an equilibrium sandwich ELISA assay (Fig. 4E). Half maximal
binding of peptide-free DR1 to MEM-264 was observed at
5.3 nM, whereas no binding was observed for peptide-loaded DR1
at concentrations up to 2 mM. Overall these data suggest that
peptide-loaded DR1 binds to MEM-264 at least 400-fold more
weakly than does peptide-free DR1.
Monoclonal antibody LB3.1. LB3.1 is a conformationally
sensitive monoclonal antibody which has three residues known to
be important in the binding interaction, all in the loop region
proximal to the a50-59 strand [38]. During the simulation,
Gln a18 does not move appreciably, Met a36 moves ,5 A´˚ but
similarly in the peptide-loaded and peptide-free models, and Lys
a39 moves and packs differently against the alpha-subunit helix in
the peptide-free and peptide-loaded models. Of these, Gln a18
and Met a36 also are in the SEC3 epitope. Differential binding of
LB3.1 to peptide-free and peptide-loaded DR1 has been observed
previously [16] but not quantified. We used SPR and ELISA to
Model for Empty MHC II
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Figure 4. Binding of peptide-loaded and peptide-free DR1 to conformationally sensitive probes. (A–C) SEC3 binding to immobilized
bio_DR. A) SPR using peptide-loaded DR1. B) SPR using peptide-free DR1. Residuals shown below SPR traces C) Equilibrium RU values vs. DR
concentration, open circles, peptide-free DR1, closed triangles, peptide-loaded DR1. (D–F) DR1 binding to immobilized MEM264. D) SPR using
peptide-loaded DR1. E) SPR using peptide-free DR1. F) ELISA of MEM264 binding empty, open circles, and loaded, closed triangles, DR1. (G–I) DR1
binding to immobilized LB3.1. G) SPR using peptide-loaded DR1. (H) SPR using peptide-free DR1.Residuals shown below. (I) ELISA of immobilized
LB3.1 binding to peptide-free (open circles) and peptide-loaded (closed triangles) DR1. (J–K) Comparison of experimental to model data. J, Ribbon
diagram of the peptide-binding site of DR1, colored by peptide-free to peptide-loaded Ca distances at the end of the dynamics runs. Larger distances
shown in darker red. K, same view but colored to indicate sites of conformational probe interaction. The yellow region represents DR1 residues that
interact with the superantigen SEC3, magenta resides that interact with the conformationally sensitive antibody LB3.1, and blue residues in the
peptide-free protein that interact with the antibody MEM264 specific for the peptide-free protein.
doi:10.1371/journal.pone.0002403.g004
Model for Empty MHC II
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quantify differences in LB3.1 binding to peptide-free and peptide-
loaded DR1. SPR analysis using immobilized LB3.1 and serial
dilutions of peptide-loaded and peptide-free DR1 indicated a
significant difference in binding kinetics (Fig 4G and H), with
tighter binding of the peptide-loaded form. Kinetic analysis
revealed apparent KD values of 76nM for peptide-loaded DR1
and 2.3nM for peptide-free DR1. We used ELISA to evaluate the
binding interaction under equilibrium conditions (Fig. 4I). Once
again, tighter binding of LB3.1 to the peptide-loaded form was
observed, with half-maximal binding observed at 0.47 nM and
2.1 nM for the peptide-loaded and peptide-free species
respectively (Table1). Overall, these experiments confirm that
peptide-free and peptide-loaded DR1 have distinct binding
affinities for LB3.1.
Discussion
Previous work has shown that peptide-free and peptide-loaded
forms of DR1 have different physical characteristics, including
hydrodynamic radius, chemical and thermal stability, and far-UV
CD and near-UV fluorescence spectra [9]. In general, these
changes can be induced by binding a wide variety of peptides
regardless of length, affinity, or sequence characteristics, provided
that the P1 site is occupied [10,39]. These observations support the
notion that there are conformationally distinct forms of the protein
based on peptide occupancy [9,11,40,41,42,43,44]. Our goal in
this work was to gain insight into structural changes that can occur
in the absence of bound peptide. Because conditions for
crystallization of peptide-free DR1 have yet to be determined, it
is necessary to approach structural questions by alternative
methods. Using molecular dynamics in conjunction with exper-
imental data can help to elucidate particular structural events that
might otherwise remain obscure.
Two important features of the interaction of peptides with class
II MHC proteins have been identified: hydrogen bonds between
conserved MHC residues and the peptide main chain amides, and
binding of several peptide side chains into pockets in the MHC
peptide binding site [2]. Hydrogen bonding interactions involving
the peptide N-terminal region in general appear to be more
important than those involving the C-terminal region [2], and for
DR1 variants the P1 pocket dominates the overall peptide binding
behavior [10,45,46]. In the molecular dynamics model for the
peptide-free form of DR1, the key hydrophobic P1 pocket
becomes engaged by Phe a54, and the secondary pocket P4 by
Gln a57. Conserved MHC hydrogen bonding residues along the
peptide binding groove become engaged by the a50-59 loop
region. By the end of the simulation, the peptide-free DR1 has
satisfied all of the N-terminal binding interactions that were lost by
initial removal of the peptide in a manner consistent with the
original bonds made by the peptide-DR1 interaction.
We used conformationally-dependent antibody and superanti-
gen probes in order evaluate the concordance of the model with
experimental data. Overall, there is good agreement between the
predicted MHC backbone movement and the degree to which the
probes are sensitive to the presence or absence of peptide (Fig. 4J
and K). The SEC3 epitope is predicted to remain stationary, and
our data show no significant differences in binding to peptide-
loaded and peptide-free DR1. The MEM264 epitope overlaps
with an area in the peptide binding region predicted to undergo a
large global movement upon peptide release, and previous results
[16] and those shown here demonstrate a dramatic difference in
the reactivity of this antibody for peptide-loaded and peptide-free
DR1. The LB3.1 epitope has not been comprehensively mapped,
although a few residues within the epitope have been identified
using DR-IE (human-mouse) chimeric molecules [38] Residues
Gln a18 and Met a36 are also included in the SEC3 epitope, but
Lys a39 is unique to the LB3.1 epitope. This residue undergoes a
rigid body as well as a side chain reorientation movement in the
model. Partial shielding of the residue could account for the
observed difference in LB3.1 binding to peptide-free and peptide-
loaded DR1, although it is possible that other residues not yet
identified contribute to LB3.1 binding. Overall, the observed
binding to peptide-free and peptide-loaded DR1 for each of the
conformational probes that we tested was consistent with
predictions from the molecular dynamics models for the peptide-
free protein. While this concordance indicates that molecular
dynamics may provide a useful model for the peptide-free
conformation, none of the available conformational probes
directly addresses the key prediction of motion of a50–59 into
the peptide binding site, which remains to be validated
experimentally.
Peptide-free DR1 has been shown to exist in at least two
kinetically defined states, peptide receptive and peptide averse
[9,10,11,13,40]. The peptide receptive form is observed immedi-
ately after release of a bound peptide, and is characterized by
rapid binding of added peptide. In the absence of peptide, the
peptide-receptive form converts to the peptide-averse form, with
t1/2,min [11]. The peptide-averse form binds peptide much more
slowly, in a process that requires a slow unimolecular conforma-
tional change [13]. The predicted conformational change in the
Table 1. Antibody and Superantigen Binding Properties of





SPR2 (n = 1) kon (M
21 s21) 22,000 (1270) 18,000 (1900)
koff (s
21) 0.25 (0.01) 0.25 (0.01)
KD
3 (nM) 11,000 (1140) 15,000 (1150)
KD
4 (nM) 6100 (500) 8000 (200)
SPR5 (n = 1) kon (M
21 s21) 1930 (88) 1900 (19)
koff (s
21) 0.012 (0.001) 0.012 (0.001)
KD 6000 (300) 6100 (110)
MEM264-DR1 interaction
SPR6 (n = 2) kon (M
21 s21) Not observed 10,500 (5800)
koff (s
21) Not observed 9000
KD (nM) .2000 24 (11)
ELISA6 (n = 3) C1/2
7 (nM) .2000 5.3 (0.7)
[16] C1/2
7 (nM) Not determined 31
LB3.1-DR1 interaction
SPR8 (n = 4) kon (M
21 s21) 554,000 (10000) 45,600 (8200)
koff (s
21) 0.00017 (0.00006) 0.00165 (0.00017)
KD (nM) 2.3 (0.5) 76 (6.6)
ELISA8 (n = 3) C1/2
7 (nM) 0.47 (0.15) 2.1 (0.39)
1Values in parentheses indicate standard errors.
2Immobilized biotinylated-DR1 with SEC3 in the mobile phase.
3KD determined by kinetic analysis of on and off rates.
4KD determined from Scatchard analysis of the equilibrium values.
5Immobilized SEC3 with DR1 in the mobile phase.
6Immobilized MEM264 with DR1 in the mobile phase.
7Concentration required for half-maximal binding signal.
8Immobilized LB3.1 with DR1 in the mobile phase.
doi:10.1371/journal.pone.0002403.t001
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peptide-free model could account for the peptide averse form of
DR1. It is plausible that upon peptide release, the binding groove
is not obstructed and therefore could bind subsequent peptide
directly, whereas once the peptide binding groove is engaged by
the a50-59 region, the protein would be in the peptide-averse
form, and would have to undergo a conformational change in
order to allow space for the peptide to enter the binding groove.
In addition to catalyzing peptide binding and release, the
peptide exchange factor HLA-DM has also been shown to stabilize
the peptide-receptive form of MHC II and to prevent conversion
to the inactive form [14,15,47,48]. A key residue in the interaction
with DM and DR1 is DR1 Phe a51. When Phe a51 is mutated to
Val or Ser the catalytic ability of DM is abolished [49].
Interpreting this result in light of the dynamics model, interaction
of DM with this residue could prevent the a50-59 region from
engaging the peptide binding groove, inhibiting formation of the
averse form. Interestingly, occlusion of the P1 pocket of DR1 by
Glyb86Tyr also has been reported to abolish DM activity [39,50].
Such a mutation might prevent a50-59 closing into the peptide
binding site, and in fact reduced formation of a peptide-averse
state has been reported for this mutant [39,50].
The structures of class I and class II MHC proteins are similar,
despite having different domain/subunit organizations and
different modes of peptide binding [51]. The a50-59 region,
proposed herein to occupy the HLA-DR peptide binding site in
the absence of peptide, represents a prominent difference between
the structures of class I and class II MHC proteins [51]. In class I
MHC proteins, the a1 helix continues unbroken through this
region, extending from residue 56 (equivalent to HLA-DR a52) to
residue 86 (equivalent to HLA-DR a78), whereas in class II MHC
proteins, this region is an extended strand interrupting flanking
helical regions. This structural difference may be related to
differences in the conformational changes induced in the absence
of peptide, which have been characterized for both class I [52,53]
and class II MHC proteins [9,42,43]. A crystal structure of a class I
MHC protein with a pentapeptide epitope occupying only the C-
terminal end of the binding site [54] and molecular dynamics
studies of peptide-free class I MHC proteins [55,56] suggest that
for class I MHC proteins the N-terminal side of the peptide
binding site could be conformationally stable in the absence of
peptide, with conformational changes predicted in the C-terminal
end [55,56]. By contrast, crystal structures of class II MHC-
peptide complexes carrying truncated penta-, hexa-, and hepta-
peptide analogs occupy the N-terminal side of the peptide binding
site, leaving the C-terminal end empty but not conformationally
altered [57]. Recently, a study of dipeptide-triggered ligand
exchange of HLA-DR1 suggested that short peptides can prevent
closure of the N-terminal side of the peptide-binding site predicted
by molecular dynamics to occur in the absence of peptide [34].
Finally, normal mode analysis of HLA-A2 [33] and HLA-DR1
[33] also highlighted differences between their potential dynamic
motions, with the N-terminal side of the binding site predicted to
be more flexible for class II MHC proteins and the C-terminal side
more flexible for class I MHC protein.
In summary, this work presents a molecular model for the
conformational change induced by peptide removal from an
MHC II protein. The model was derived from molecular
dynamics calculations and tested using experimental conforma-
tional probes. Development of a model for the peptide-free form of
DR1 can help to interpret the conformational changes known to
occur within the protein during peptide binding and release, and
can provide insight into possible mechanisms for DM action.
Supporting Information
Figure S1 Conformational variation in DR1 crystal structures.
A, Overlay of crystallographically distinct ab heterodimers from
three crystal structures reported for DR1-peptide complexes
solved in the absence of superantigen. B, RMS Ca distances for
aligned ab heterodimers, with mean RMS in each domain
indicated. Structures aligned using LSQMAN [59].
Found at: doi:10.1371/journal.pone.0002403.s001 (4.36 MB TIF)
Figure S2 Difference distance matrix between the peptide-
loaded and peptide-free conformations of HLA-DR1. The blue
squares show areas in the protein that move away from each other
in the peptide-free model when compared to the peptide-loaded
conformation, with stronger blue intensity for the areas that are
the further apart (15 A˚ difference) and lighter blue for the areas
that move away but not as much (4 A˚ difference). The red squares
show regions on the peptide-free form that move closer to other
regions in the protein when compared to peptide-loaded HLA-
DR1; intense red color are areas that move more. The gray
squares are regions that do not change as much (0–3.99 A˚).
Found at: doi:10.1371/journal.pone.0002403.s002 (4.79 MB TIF)
Figure S3 Characterization of peptide loaded and peptide-free
DR1. A, analysis of peptide-free DR1 and peptide-loaded DR1 by
gel filtration (Superdex 200). Peptide-free DR1 (dotted line) has a
larger hydrodynamic radius the peptide-loaded DR1(solid line).
Arrows indicate position and molecular weight of standard
proteins. X axis represents time in minutes, Y axis represents
optical density (milli OD). B, 12% SDS-PAGE analysis of peptide-
free DR1 and peptide-loaded DR1. Peptide-free DR1 dissociates
into alpha beta subunits in SDS whereas peptide-loaded DR1 is
resistant to SDS dissociation until boiled.
Found at: doi:10.1371/journal.pone.0002403.s003 (3.27 MB TIF)
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